The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in income, its intellectual property lapse created a wave of lower-priced alternatives , significantly diminishing its dominance. While specific businesses may attempt to capitalize on related treatments